A 1-year, open-label, flexible-dosage study to evaluate the safety and continued efficacy of modafinil (film-coated tablet formulation) in children and adolescents with attention-deficit/hyperactivity disorder (followed by an open-ended extension period)

Trial Profile

A 1-year, open-label, flexible-dosage study to evaluate the safety and continued efficacy of modafinil (film-coated tablet formulation) in children and adolescents with attention-deficit/hyperactivity disorder (followed by an open-ended extension period)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2012

At a glance

  • Drugs Modafinil (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Cephalon
  • Most Recent Events

    • 25 Jul 2012 Company (Teva Pharmaceutical Industries) added in association as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Actual initiation date (Sep 2003) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top